CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Photocure ASA

PHO.OL
$130MMicro Cap

Next catalyst

Phase 3January 2027

Cysview

Bladder Cancer

Get an email about PHO.OL's next catalysts

Track Photocure ASA (PHO.OL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 0 past

Phase 3Next

Cysview Phase 3 Est. Readout

January 2027~Cysview200

Estimated primary completion for Cysview trial (NCT06525571) in Bladder Cancer. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

Oslo BorsPharmaceutical Preparations🇳🇴EuropeOslo99 employees
Drug Pipeline

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Photocure ASA's drug pipeline?→

CatalystAlert tracks 15 drug candidates in Photocure ASA's (PHO.OL) pipeline across Phase 3, Phase 2. Its lead program is Cysview (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Photocure ASA's next FDA catalyst?→

Photocure ASA's (PHO.OL) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track PHO.OL biotech catalysts?→

Add PHO.OL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Photocure ASA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply